On Wednesday, Glu Mobile, Inc. (NASDAQ:GLUU)’s shares gained 2.91%, and closed at $5.12, as a leading global developer and publisher of free-to-play games for smartphone and tablet devices, declared that it will report its financial results for the first quarter ended March 31, 2015 after the U.S. markets close on Wednesday, April 29, 2015.
In conjunction with this declaration, Glu will host a conference call on April 29, 2015 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to talk about the corporation’s financial results. To access this call, dial (866) 582-8907 (domestic), or (760) 298-5046 (international), with conference ID #20787035. A replay of this conference call will be accessible between 4:30 p.m. PT, April 29, 2015 and 8:59 p.m. PT, May 6, 2015 by calling (855) 859-2056, or (404) 537-3406, with conference ID #20787035.
Glu Mobile Inc. develops, publishes, and markets a portfolio of games for the smartphones and tablet devices users. The corporation offers free-to-play action, casual, racing, and sports genre mobile games.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s shares jumped 2.76%, and settled at $123.79, during the last trading session on Wednesday, as on March 23, Vertex Pharmaceuticals declared data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 (100 mg once daily or 50 mg every 12 hours) in combination with ivacaftor (150 mg every 12 hours). The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients accomplished 12 weeks of treatment. The most ordinary adverse events were pulmonary exacerbation, which occurred in 38 percent of all patients who received VX-661 and 44 percent of those who received placebo, and cough, which occurred in 33 percent of all patients who received VX-661 and 39 percent of those who received placebo.
Secondary endpoints evaluated the effect of the combination on lung function (percent predicted forced expiratory volume in one second; ppFEV1), and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacaftor (n=15) was 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively. Consistent with preceding Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients accomplished treatment, lung function returned to baseline.
These safety and efficacy data, together with other data from multiple formerly accomplished Phase 2 studies of VX-661, support Vertex’s ongoing Phase 3 program of VX-661 in combination with ivacaftor. The Phase 3 program is evaluating VX-661 (100 mg once daily) in combination with ivacaftor (150 mg every 12 hours) and comprises of four Phase 3 studies, counting a study in people with two copies of the F508del mutation that began enrollment in February. The other three studies will enroll people with CF who have one copy of the F508del mutation and a second mutation that is either a gating mutation, residual function mutation or a mutation that results in minimal CFTR function.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The corporation focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
At the end of Wednesday’s trade, American Airlines Group Inc. (NASDAQ:AAL)’s shares climbed 2.62%, and closed at $48.74, after American Airlines, received a single operating certificate from the Federal Aviation Administration (FAA) for American and US Airways, marking a major milestone in the integration of the two airlines.
The FAA’s approval for American and US Airways to operate under one certificate is the culmination of more than 18 months of work aligning the carriers’ operating policies and procedures. Starting recently, most flight operations, maintenance and dispatch procedures will be identical for all flights. Air traffic control communications will refer to all American and US Airways flights with the call sign “American.”
A team of more than 700 employees reviewed 465 manuals together with policies, procedures and programs from both carriers and selected best practices to implement for the merged airline. More than 110,000 employees accomplished hundreds of thousands of hours of training in multiple phases and more than 115,000 pages on policies and procedures were published.
Since American and US Airways merged in December 2013, the airline has been making steady integration progress, counting inducting US Airways into the oneworld alliance, merging separate frequent flyer programs into the single AAdvantage program and reaching five-year joint collective bargaining contracts with its pilots and flight attendants.
American Airlines Group Inc., through its auxiliaries, operates in the airline industry. As of December 31, 2014, the corporation operated 983 mainline jets, in addition to 566 regional aircrafts through regional airline auxiliaries and third-party regional carriers. It serves 339 destinations in 54 countries.
Keurig Green Mountain, Inc. (NASDAQ:GMCR), ended its Wednesday’s trading session with 2.56% gain, and closed at $117.67, as on April 2, Dunkin’ Donuts declared that starting recently, Dunkin’ K-Cup® pods will be accessible for sale online for the first time. As part of Dunkin’ Brands’ (DNKN) expanded partnership with The J.M. Smucker Corporation (SJM) and Keurig Green Mountain (GMCR), declared in February, Dunkin’ K-Cup® pods will be sold on www.DunkinDonuts.com. The 12-count box of Dunkin’ K-Cup® pods is accessible in five varieties, counting Original Blend, Dark Roast, French Vanilla, Hazelnut, and Dunkin’ Decaf®. Dunkin’ K-Cup® pods will also be accessible in select retail locations, www.OnlineStore.Smucker.com, www.Keurig.com and other online retailers starting this summer.
Keurig Green Mountain, Inc. produces and sells specialty coffee, coffeemakers, teas, and other beverages in the United States and Canada. It sources, produces, and sells coffee, hot cocoa, teas, and other beverages under various brands in K-Cup, Vue, Rivo, K-Carafe, and Bolt portion packs brands; and coffee in traditional packaging, counting bags and fractional packs, in addition to offers whole bean and ground coffee in bags, fractional packages, and cans.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
